1. Home
  2. ALLO

as 09-08-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Founded: 2017 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 231.9M IPO Year: 2018
Target Price: $8.88 AVG Volume (30 days): 3.8M
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.11 EPS Growth: N/A
52 Week Low/High: $0.86 - $3.78 Next Earning Date: 11-06-2025
Revenue: N/A Revenue Growth: -76.84%
Revenue Growth (this year): -48.49% Revenue Growth (next year): 100.00%

ALLO Daily Stock ML Predictions

Share on Social Networks: